NEW YORK — Clinical Genomics said on Monday that New York State Department of Health has issued a permit allowing use of the company's Colvera colorectal cancer liquid biopsy test within New York state.
Colvera is now available in all 50 US states, Clinical Genomics said.
Colvera detects aberrant methylation in BCAT1 and IKZF1, two genes found at a high frequency in colorectal cancer tissue. Identification of the biomarkers can help in the management of patients previously treated for colorectal cancer who are undergoing follow-up testing to assess the presence of residual or recurrent disease.
In November, Bridgewater, New Jersey-based Clinical Genomics said that Colvera received Medicare coverage under Medicare Administrative Contractor Novitas Solution's revised local coverage determination. In July, the company's received licensure from California authorities, which allows the test to be offered there.